Research map: BRAF fusions define therapeutic vulnerability and tyrosine kinase inhibitor resistance in non-small cell lung cancer

Back to the article

Papers in this map

  1. Trimmomatic: a flexible trimmer for Illumina sequence data · Anthony Bolger · 2014 · 71940 citations · Cited by this paper
  2. Epiproteomic profiling identifies histone H4 hyperacetylation as a prognostic marker in pleural mesothelioma · 2026 · Related
  3. Signatures of mutational processes in human cancer · Australian Pancreatic Cancer Genome Initiative · 2013 · 10282 citations · Cited by this paper
  4. Neoadjuvant and perioperative chemo-immunotherapy in early-stage non-small cell lung cancer: international expert panel meeting by AIOT · 2026 · Related
  5. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation · Paul B. Chapman · 2011 · 7808 citations · Cited by this paper
  6. Real-world burden of cardiovascular events following immune checkpoint inhibitor therapy: impact on mortality and treatment resumption in 29,503 patients · 2026 · Related
  7. Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer · Jean‐Charles Soria · 2017 · 5482 citations · Cited by this paper
  8. Biology, detection, and management of incidental pulmonary nodules: the emerging role of targeted treatments. A review of the current literature and future perspectives · 2026 · Related
  9. VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing · Daniel C. Koboldt · 2012 · 5420 citations · Cited by this paper
  10. Efficacy and safety of immune checkpoint inhibitors in lung cancer patients with hepatitis B surface antigen positivity: a real-world cohort study · 2026 · Related
  11. The biology and management of non-small cell lung cancer · Roy S. Herbst · 2018 · 5124 citations · Cited by this paper
  12. Time-dependent bias in local consolidative therapy for EGFR-mutant metastatic non-small cell lung cancer · 2026 · Related
  13. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden · Zachary Rockow Chalmers · 2017 · 3804 citations · Cited by this paper
  14. Clonal divergence with acquired BRAF V600E in NSCLC with compound EGFR G719X/S768I after prolonged EGFR-TKI therapy · 2026 · Related
  15. Oncogenic Signaling Pathways in The Cancer Genome Atlas · Francisco Sánchez-Vega · 2018 · 3452 citations · Cited by this paper
  16. CT surveillance, patterns of recurrence and eligibility for salvage therapy after curative intent treatment for unresectable stage III non small cell lung cancer · 2026 · Related
  17. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer · Tony S.K. Mok · 2016 · 3397 citations · Cited by this paper
  18. First-line treatment for unresectable pulmonary lymphoepithelial carcinoma: A real-world comparison of platinum-based doublet chemotherapy with or without PD-1 inhibitors · 2026 · Related
  19. Targeting RAS signalling pathways in cancer therapy · Julian Downward · 2003 · 3293 citations · Cited by this paper
  20. Development and validation of a risk-stratification model for individualized management of leptomeningeal metastases in EGFR- mutant NSCLC (LM-Index) · 2026 · Related
  21. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial · Axel Hauschild · 2012 · 3016 citations · Cited by this paper
  22. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib · Caroline Robert · 2014 · 2727 citations · Cited by this paper
  23. Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma · James Larkin · 2014 · 2083 citations · Cited by this paper
  24. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma · Georgina Venetia Long · 2014 · 1919 citations · Cited by this paper
  25. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer · Alessandro Leonetti · 2019 · 1444 citations · Cited by this paper
  26. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing · Ronglai Shen · 2016 · 1350 citations · Cited by this paper
  27. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial · Yi-Long Lung Cancer Wu · 2017 · 1233 citations · Cited by this paper
  28. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy · Ferdinandos Skoulidis · 2019 · 1058 citations · Cited by this paper
  29. Understanding and targeting resistance mechanisms in NSCLC · Julia K. Rotow · 2017 · 1040 citations · Cited by this paper
  30. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial · David Planchard · 2016 · 898 citations · Cited by this paper
  31. New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical Trials · William David Travis · 2013 · 603 citations · Cited by this paper
  32. Non-small-cell lung cancer · Lizza E.L. Hendriks · 2024 · 548 citations · Cited by this paper
  33. The clinical development of MEK inhibitors · Yujie Zhao · 2014 · 414 citations · Cited by this paper
  34. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy · Jeffrey S. Ross · 2015 · 360 citations · Cited by this paper
  35. MEK inhibitors for the treatment of non-small cell lung cancer · Jing Han · 2021 · 300 citations · Cited by this paper
  36. The KEAP1-NRF2 pathway: Targets for therapy and role in cancer · Simone Adinolfi · 2023 · 291 citations · Cited by this paper
  37. Advances and challenges in therapeutic targeting of NRF2 · Albena T. Dinkova‐Kostova · 2023 · 269 citations · Cited by this paper
  38. BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition · Katherine E. Hutchinson · 2013 · 182 citations · Cited by this paper
  39. Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors · Alexa Betzig Schrock · 2018 · 140 citations · Cited by this paper

Source: OpenAlex (CC0)